|1.||Uckun, Fatih M: 3 articles (03/2012 - 12/2004)|
|2.||D'Cruz, Osmond J: 2 articles (03/2012 - 12/2004)|
|3.||Qazi, Sanjive: 1 article (03/2012)|
|4.||Yiv, Seang: 1 article (03/2012)|
|5.||Erbeck, Douglas: 1 article (01/2007)|
|6.||Venkatachalam, Taracad K: 1 article (01/2007)|
|7.||Tibbles, Heather E: 1 article (01/2007)|
|8.||Samuel, Peter: 1 article (12/2004)|
|1.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/2007 - "HI-443 was very well tolerated in CD-1 mice and Lewis rats without any detectable toxicity at single parenteral bolus dose levels as high as 80 mg/kg. Intraperitoneally administered HI-443 exhibited anti-HIV activity in the Hu-PBL-SCID mouse surrogate model for hunnan AIDS at a non-toxic daily dose level of 10-20 mg/kg. These preclinical research studies provide the basis for future preclinical studies and clinical development of HI-443 as a new NNRTI candidate."
03/01/2012 - "Intravaginally administered HI-443 prevented vaginal transmission of a drug-resistant clinical HIV-1 isolate in the surrogate Hu-PBL-SCID mouse model of AIDS. "
12/01/2004 - "PHI-443 completely prevented the vaginal transmission of a genotypically and phenotypically drug-resistant HIV-1 isolate in the humanized severe combined immunodeficient (Hu-SCID) mouse model of sexually transmitted AIDS. "